Role of toll-like receptors in immune responses to chlamydial infections

Current Pharmaceutical Design

Volumn 14, Issue 6, 2008, Pages 593-600

  Joyee, A G ^a   Yang, Xi ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chlamydia; MyD88; Toll like receptor

Indexed keywords

ADAPTOR PROTEIN; BACTERIAL VACCINE; BACTERIUM LIPOPOLYSACCHARIDE; CPG OLIGODEOXYNUCLEOTIDE; HEAT SHOCK PROTEIN 60; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; YELLOW FEVER VACCINE;

CHLAMYDIA; CHLAMYDIASIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION RESISTANCE; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; CHLAMYDOPHILA PNEUMONIAE; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; TOLL-LIKE RECEPTORS;

EID: 42049097685     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208783885344     Document Type: Review

References (87)

1. World Health Organization. Global prevalence and incidence of selected curable sexually transmitted infections-overviewed and estimates WHO/CDS/ CSR/EDC/2001.10.2001: 1-48.
2. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8(4):451-61.
3. Johnston SC, Messina LM, Browner WS, Lawton MT, Morris C, Dean D. C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis. Stroke 2001; 32(12): 2748-52.
4. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, et al. Identification and localization of Chlamydia pneumoniae in the Atzheimer's brain. Med Microbiol Immunol (Berl) 1998; 187(1):23-42.
5. Grimaldi LM, Pincherle A, Martinelli-Boneschi F, Filippi M, Patti F, Reggio A, et al. An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients. Mult Scler 2003; 9(5): 467-71.
6. Yang X, HayGlass KT, Brunham RC. Genetically determined differences in IL-10 and IFN-gamma responses correlate with clearance of Chlamydia trachomatis mouse pneumonitis infection. J Immunol 1996; 156(11): 4338-44.
7. Penttila JM, Anttila M, Puolakkainen M, Laurila A, Varkila K, Sarvas M, et al. Local immune responses to Chlamydia pneumoniae in the lungs of BALB/c mice during primary infection and reinfection. Infect Immum 1998; 66(11): 5113-8.
8. Rottenberg ME, Gigbotti Rothfuchs AC, Gigliotti D, Svanholm C, Bandholtz L, Wigzell H. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol 1999; 162(5): 2829-36.
9. Wang S, Fan Y, Brunham RC, Yang X. IFN-gamma knockout mice show Th2-associated delayed-type hypersensitivity and the inflammatory cells fail to localize and control chlamydial infection. Eur J Immunol 1999; 29 (11): 3782-92.
10. Akira S, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2(8): 675-80.
11. Takeda K, Akira S. Microbial recognition by Toll-Eke receptors. J Dermatol Sci 2004; 34(2): 73-82.
12. Barton GM, Medzhitov R. Toll-like receptor signaling pathways. Science 2003; 300(5625): 1524-5.
13. O'Neill LA. Toll-like receptor signal transduction and the tailoring of innate immunity: A role for Mal? Trends Immunol 2002; 23(6): 296-300.
14. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430(6996): 257-63.
15. Takeda K, Kaisho T, Akira S. Toll-like receptors. Anna Rev Immunol 2003; 21: 335-76.
16. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4(7): 499-511.
17. Pandey S, Agrawal DK. Immunobiology of toll-tike receptors: Emerging trends. Immunol Cell Biol 2006; 84(4): 333-41.
18. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85(2): 85-95.
19. Chopra I, Storey C, Falla TJ, Pearce JH. Antibiotics, peptidoglycan synthesis and genomics: The chlamydial anomaly revisited. Microbiology 1999; 144 (Pt 10): 2673-8.
20. Moulder JW. Why is Chlamydia sensitive to penicillin in the absence of peptidoglycan? Infect Agents Dis 1993; 2(2): 87-99.
21. O'Connell GM, Ionova IA, Quayle AJ, Visintin A, Ingalls RR. Localization of TLR2 and MyD88 to Chlamydia trachomatis inclusions. Evidence for signaling by intracellular TLR2 during infection with an obligate intracellular pathogen. J Biol Chem 2006; 281(3): 1652-9.
22. Wyllie DH, Kiss-Toth E, Visintin A, Smith SC, Boussouf S, Segal DM, et al. Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses. J Immunol 2000; 165(12): 7125-32.
23. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97(25): 13766-71.
24. Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via toll-like receptor 2. J Med Microbiol 2004; 53(Pt 8): 735-40.
25. Ghuysen JM, Goffin C. Lack of cell wall peptidoglycan versus penicillin sensitivity: New insights into the chlamydial anomaly. Antimicrob Agents Chemother 1999; 43(10): 2339-44.
26. Prebeck S, Kirschning C, Durr S, da Costa C, Donah B, Brand K, et al. Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol 2001; 167(6): 3316-23.
27. Netea MG, Kullberg BJ, Galama JM, Stalenhoef AF, Dinarello CA, Van der Meer JW. Non-LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll-like receptor 2-dependent pathways. Eur J Immunol 2002; 32(4): 1188-95.
28. Netea MG, Van der Meer JW, Sutmuller RP, Adema GJ, Kullberg BJ. From the Th1/Th2 paradigm towards a Toll-like receptor/T-helper bias. Antimicrob Agents Chemother 2005; 49(10): 3991-6.
29. Darville T, O'Neill JM, Andrews CW Jr, Nagarajan UM, Stahl L, Ojcius DM. Toll-like receptor-2, but not Toll-hke receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol 2003; 171(11): 6187-97.
30. Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect Immun 2000; 68(5): 2870-9.
31. Yang X, Gartner J, Zhu L, Wang S, Branham RC. IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J Immunol 1999; 162(2): 1010-7.
32. Naiki Y, Michelsen KS, Schroder NW, Alsabeh R, Slepenkin A, Zhang W, et al. MyD88 is pivotal for the early inflammatory response and subsequent bacterial clearance and survival in a mouse model of Chlamydia pneumoniae pneumonia. J Biol Chem 2005; 280(32): 29242-9.
33. Yaraei K, Campbell LA, Zhu X, Liles WC, Kuo CC, Rosenfeld ME. Effect of Chlamydia pneumoniae on cellular ATP content in mouse macrophages: Role of Toll-like receptor 2. Infect Immun 2005; 73(7): 4323-6.
34. Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Infect Immun 2007; 75(2): 753-9.
35. Rank RG. Models of immunity. In: Stephens RS, Ed, Chlamydia; intracellular biology, pathogenesis, and immunity. Washington, DC: American Society for Microbiology Press 1999; 239-95.
36. Ward ME, Mechanisms of Chlamydia-induced disease. In: Stephens RS, Ed, Chlamydia: Intracellular biology, pathogenesis, and immunity. Washington, DC: American Society for Microbiology. Press 1999; 171-210.
37. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998; 98(4): 300-7.
38. Bulut Y, Faure E, Thomas L, Karahashi H, Michelsen KS, Equils O, et al. Chlamydial heat shock protein 60 activates macrophages and endothelial cells through toll-like receptor 4 and MD2 in a MyD88-dependent pathway. J Immunol 2002; 168(3): 1435-40.
39. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89(3): 244-50.
40. Haralambieva IH, Iankov ID, Ivanova PV, Mitev V, Mitov IG. Chlamydophila pneumoniae induces p44/p42 mitogen-activated. protein kinase activation in human fibroblasts through Toll-like receptor 4. J Med Microbiol 2004; 53(Pt 12): 1187-93.
41. Costa CP, Kirschning CJ, Busch D, Durr S, Jennen L, Heinzmann U, et al. Role of chlamydial heat shock protein 60 in the stimulation of innate immune cells by Chlamydia pneumoniae. Eur J Immunol 2002; 32(9): 2460-70.
42. Da Costa CU, Wantia N, Kirschning CJ, Busch DH, Rodriguez N, Wagner H, et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. Eur J Immumol 2004; 34(10): 2874-84.
43. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007; 19(1): 3-10.
44. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296(5566): 301-5.
45. Fazeli A, Bruce C, Anumba DO. Characterization of Toll-like receptors in the female reproductive tract in humans. Hum Reprod 2005; 20(5): 1372-8.
46. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164(2): 558-61.
47. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ,, Hacker H, et al. Endocyytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276(33): 31332-9.
48. Vabulas RM, Wagner H, Schild H. Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol 2002; 270: 169-84.
49. Perfettini JL, Ojcius DM, Andrews CW Jr, Korsmeyer SJ, Rank RG, Darville T. Role of proapoptotic BAX in propagation of Chlamydia muridarum (the mouse pneumonitis strain of Chlamydia trachomatis) and the host inflammatory response. J Biol Chem 2003; 278(11): 9496-502.
50. Mueller M, Postius S, Thimm JG, Gueinzius K, Muehldorfer I, Hermann C. Toll-like receptors 2 and 4 do not contribute to clearance of Chlamydophila pneumomae in mice, but are necessary for the release of monokines. Immunobiology 2004; 209(8): 599-608.
51. Rodriguez N, Wantia N, Fend F, Durr S, Wagner H, Miethke T. Differential involvement of TLR2 and TLR4 in host survival during pulmonary infection with Chlamydia pneumoniae. Eur J Immunol 2006; 36(5): 1145-55.
52. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest 2003; 112(8): 1234-43.
53. Reiling N, Holscher C, Fehrenbach A, Kroger S, Kirschning CJ, Goyert S, et al. Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 2002; 169(7): 3480-4.
54. Hayashi EA, Akira S, Nobrega A. Role of TLR in B cell development: signaling through TLR4 promotes B cell maturation and is inhibited by TLR2. J Immunol 2005; 174(11): 6639-47.
55. Trumstedt C, Eriksson E, Lundberg AM, Yang TB, Yan ZQ Wigzell H, et al. Role of IRAK4 and IRF3 in the control of intracellular infection with Chlamydia pneumoniae. J Leukoc Biol 2007; 81(6): 1591-8.
56. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999; 11 (4): 443-51.
57. Muraille E, De Trez C, Brait M, De Baetselier P, Leo O, Carlier Y. Genetically resistant mice lacking MyD88-adapter protein display a high sasceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 2003; 170(8): 4237-41.
58. Scanga CA, Bafica A, Feng CG, Cheever AW, Hieny S, Sher A. MyD88-deficient mice display a profound loss in resistance to Mycobacterium tuberculosis associated with partially impaired Th1 cytokine and nitric oxide synthase 2 expression. Infect Immun 2004; 72(4): 2400-4.
59. Rodriguez N, Fend F, Jennen L, Schiemann M, Wantia N, Prazeres da Costa CU, et al. Polymorphonuclear neutrophils improve replication of Chlamydia pneumoniae in vivo upon MyD88-dependent attraction. J Immunol 2005; 174(8): 4836-44.
60. Nagarajan UM, Ojcius DM, Stahl L, Rank RG, Darville T. Chlamydia trachomatis induces expression of IFN-gamma-inducible protein 10 and IFN-beta-independent of TLR2 and TLR4, but largely dependent on MyD88. J Immunol 2005; 175(1): 450-60.
61. Rothfuchs AG, Trumstedt C, Wigzell H, Rottenberg ME. Intracellular bacterial infection-induced IFN-gamma is critically but not solely dependent on Toll-like receptor 4-myeloid differentiation factor 88-IFN-alpha beta-STAT1 signaling. J Immunol 2004; 172(10): 6345-53.
62. Heine H, Muller-Loennies S, Brade L, Lindner B, Brade H. Endotoxic activity and chemical structure of lipopolysaccharides from Chlamydia trachomatis serotypes-E and L2 and Chlamydophila psittaci 6BC. Eur J Biochem 2003; 270(3): 440-50.
63. Netea MG, Kullberg BJ, Jacobs LE, Verver-Jansen TJ, van der Ven-Jongekrijg J, Galama JK et al. Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release. J Immunol 2004; 173(2): 1477-82.
64. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, et al. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 2004; 101(10): 3516-21.
65. Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol 2005; 35(1): 273-81.
66. Bafica A, Scanga CA, Feng CG, Leifer C, Cheever A, Sher A. TLR9 regulates Thl responses and cooperates with TLR2 in mediating optimal resistance to Mycobacterium tuberculosis. J Exp Med 2005; 202(12): 1715-24.
67. Bandholtz L, Kreuger MR, Svanholm C, Wigzell H, Rottenberg ME. Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae. Clin Exp Immunol 2002; 130(3): 393-403.
68. Han X, Fan Y, Wang S, Yang J, Bilenki L, Qiu H, et al. Dendritic cells from Chlamydia-infected mice show altered Toll-like receptor expression and play a crucial role in inhibition of allergic responses to ovalbumin. Eur J Immunol 2004; 34(4): 981-9.
69. Jain VV, Kitagaki K, Businga T, Hussain I, George C, O'Shaughnessy P, et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol 2002; 110(6):867-72.
70. Bohle B. CpG motifs as possible adjuvants for the treatment of allergic diseases. Int Arch Allergy Immunol 2002; 129(3): 198-203.
71. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Sher A. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 2006; 177(6): 3515-9.
72. Goldstein DR. Toll-like receptors and other links between innate and acquired alloimmunity. Curr Opin Immunol 2004; 16(5): 538-44.
73. Opitz B, Forster S, Hocke AC, Maass M, Schmeck B, Hippehstiel S, et al. Nod1-mediated endothelial cell activation by Chlamydophila pneumoniae. Circ Res 2005; 96(3): 319-26.
74. Chamaillard M, Hashimoto M, Horie Y, Misumoto J, Qiu S, Saab L, et al. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 2003; 4(7): 702-7.
75. Girardin SE, Jehanno M, Mengin-Lecreulx D, Sansonetti PJ, Alzari PM, Philpott DJ. Identification of the critical residues involved in peptidoglycan, detection by Nod1. J Biol Chem, 2005; 280(46): 38648-56.
76. Welter-Stahl L, Qjcius DM, Viala J, Girardin S, Liu W, Delarbre C, et al. Stimulation of the cytosolic receptor for peptidoglycan, Nod1, by infection with Chlamydia trachomatis or Chlamydia muridarum. Cell Microbiol 2006; 8(6): 1047-57.
77. Sun J, Walsh M, Villarino AV, Cervi L, Hunter CA, Choi Y, et al. TLR ligands can activate dendritic cells to provide a MyD88- dependent negative signal for Th2 cell development. J Immunol 2005; 174(2): 742-51.
78. Barton GM, Medzhitov R. Control of adaptive immune responses by toll-like receptors. Curr Opin Immunol 2002; 14(3): 380-3.
79. Kaisho T, Hoshino K, Iwabe T, Takeuchi O, Yasui T, Akira S. Endotoxin can induce MyD88-deficient dendritic cells to support T(h)2 cell differentiation. Int Immunol 2002; 14(7): 695-700.
80. Pal S, Davis HL, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynuelcotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun 2002; 70(9): 4812-7.
81. Warger T, Osterloh P, Rcchtsteiner G, Fassbender M, Heib V, Schmid B, et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006; 108(2): 544-50.
82. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006; 203(2): 413-24.
83. Zhang D, Yang X, Lu H, Zhong G, Brunham RC. Immunity to Chlamydia trachomatis mouse pneumonitis induced by vaccination with live organisms correlates with early granulocyte-macrophage colony-stimulating factor and interleukin-12 production and with dendritic cell-like maturation. Infect Immun 1999; 67(4): 1606-13.
84. Mackaness GB. The relationship of delayed hypersensitivity to acquired cellular resistance. Br Med Bull 1967; 23(1): 52-4.
85. Netea MG, Ferwerda G, van der Graaf CA, Van der Meer JW, Kullberg BJ. Recognition of fungal pathogens by toll-like receptors. Curr Pharm Des 2006; 12(32): 4195-201.
86. Pepe M, Altamura M, Spinelli R, Calvello R, Saccia M, Cavallo P, et al. Toll-like receptor-positive cells and recognition of pathogens: how human myeloid dendritic cells respond to in vitro infection with Leishmania infantum. Curr Pharm Des 2006; 12(32): 4255-62.
87. Stoll LL, Denning GM, Weintraub NL. Endotoxin, TLR4 signaling and vascular inflammation: Potential therapeutic targets in cardiovascular disease. Curr Pharm Des 2006; 12(32): 4229-45.